{
    "Symbol": "NVO",
    "AssetType": "Common Stock",
    "Name": "Novo Nordisk A/S",
    "Description": "Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.",
    "CIK": "353278",
    "Exchange": "NYSE",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "PHARMACEUTICAL PREPARATIONS",
    "Address": "NOVO ALLE DK 2880, BAGSVAERD DENMARK, DK",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2023-12-31",
    "MarketCapitalization": "590691893000",
    "EBITDA": "109812998000",
    "PERatio": "48.31",
    "PEGRatio": "2.4",
    "BookValue": "23.9",
    "DividendPerShare": "9.4",
    "DividendYield": "0.0104",
    "EPS": "2.74",
    "RevenuePerShareTTM": "51.81",
    "ProfitMargin": "0.36",
    "OperatingMarginTTM": "0.428",
    "ReturnOnAssetsTTM": "0.234",
    "ReturnOnEquityTTM": "0.881",
    "RevenueTTM": "232260993000",
    "GrossProfitTTM": "148506000000",
    "DilutedEPSTTM": "2.74",
    "QuarterlyEarningsGrowthYOY": "0.631",
    "QuarterlyRevenueGrowthYOY": "0.37",
    "AnalystTargetPrice": "139.7",
    "AnalystRatingStrongBuy": "2",
    "AnalystRatingBuy": "4",
    "AnalystRatingHold": "1",
    "AnalystRatingSell": "0",
    "AnalystRatingStrongSell": "0",
    "TrailingPE": "48.31",
    "ForwardPE": "39.06",
    "PriceToSalesRatioTTM": "2.543",
    "PriceToBookRatio": "37.74",
    "EVToRevenue": "2.533",
    "EVToEBITDA": "5.13",
    "Beta": "0.175",
    "52WeekHigh": "138.28",
    "52WeekLow": "70.25",
    "50DayMovingAverage": "117.75",
    "200DayMovingAverage": "98.11",
    "SharesOutstanding": "4462430000",
    "DividendDate": "2024-04-02",
    "ExDividendDate": "2024-03-22"
}